Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Inhibiting SARS-CoV-2 infection in vitro by suppressing its receptor, angiotensin-converting enzyme 2, via aryl-hydrocarbon receptor signal.

Tytuł:
Inhibiting SARS-CoV-2 infection in vitro by suppressing its receptor, angiotensin-converting enzyme 2, via aryl-hydrocarbon receptor signal.
Autorzy:
Tanimoto K; Department of Radiation Disaster Medicine, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, 734-8553, Japan. .
Hirota K; Department of Human Stress Response Science, Institute of Biomedical Science, Kansai Medical University, Hirakata, 573-1010, Japan.
Fukazawa T; Natural Science Center for Basic Research and Development, Hiroshima University, Hiroshima, 734-8553, Japan.
Matsuo Y; Department of Human Stress Response Science, Institute of Biomedical Science, Kansai Medical University, Hirakata, 573-1010, Japan.
Nomura T; Department of Virology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, 734-8553, Japan.
Tanuza N; Department of Virology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, 734-8553, Japan.
Hirohashi N; Department of Radiation Disaster Medicine, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, 734-8553, Japan.
Bono H; Program of Biomedical Science, Graduate School of Integrated Sciences for Life, Hiroshima University, Higashi-Hiroshima, 739-0046, Japan.
Sakaguchi T; Department of Virology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, 734-8553, Japan.
Źródło:
Scientific reports [Sci Rep] 2021 Aug 17; Vol. 11 (1), pp. 16629. Date of Electronic Publication: 2021 Aug 17.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Original Publication: London : Nature Publishing Group, copyright 2011-
MeSH Terms:
COVID-19 Drug Treatment*
Angiotensin-Converting Enzyme 2/*antagonists & inhibitors
Basic Helix-Loop-Helix Transcription Factors/*agonists
Carbazoles/*pharmacology
Omeprazole/*pharmacology
Receptors, Aryl Hydrocarbon/*agonists
Angiotensin-Converting Enzyme 2/genetics ; Angiotensin-Converting Enzyme 2/metabolism ; Animals ; Basic Helix-Loop-Helix Transcription Factors/metabolism ; COVID-19/virology ; Carbazoles/therapeutic use ; Chlorocebus aethiops ; Cytochrome P-450 CYP1A1/metabolism ; Dose-Response Relationship, Drug ; Drug Evaluation, Preclinical ; Gene Expression Regulation/drug effects ; Gene Knockdown Techniques ; Hep G2 Cells ; Humans ; Omeprazole/therapeutic use ; RNA-Seq ; Receptors, Aryl Hydrocarbon/metabolism ; SARS-CoV-2/drug effects ; SARS-CoV-2/pathogenicity ; Signal Transduction/drug effects ; Vero Cells ; Virus Internalization/drug effects
References:
Nature. 2020 Mar;579(7798):270-273. (PMID: 32015507)
Lung. 2020 Dec;198(6):867-877. (PMID: 33170317)
J Invest Dermatol. 2019 May;139(5):1098-1109. (PMID: 30503244)
Curr Med Chem. 2012;19(1):63-9. (PMID: 22300077)
Nicotine Tob Res. 2020 Aug 24;22(9):1650-1652. (PMID: 32242236)
Annu Rev Pharmacol Toxicol. 2003;43:309-34. (PMID: 12540743)
Proc Natl Acad Sci U S A. 2020 Mar 31;117(13):7001-7003. (PMID: 32165541)
Toxicol Sci. 2015 May;145(1):5-15. (PMID: 25911656)
Lancet Infect Dis. 2020 Sep;20(9):1034-1042. (PMID: 32422204)
medRxiv. 2020 Dec 11;:. (PMID: 33330896)
Nucleic Acids Res. 2018 Jan 4;46(D1):D380-D386. (PMID: 29087512)
Tob Induc Dis. 2020 May 06;18:37. (PMID: 32382258)
Nat Commun. 2019 Apr 3;10(1):1523. (PMID: 30944313)
Tob Induc Dis. 2020 Mar 20;18:20. (PMID: 32206052)
EMBO J. 2000 Aug 15;19(16):4298-309. (PMID: 10944113)
Antioxidants (Basel). 2021 Jan 03;10(1):. (PMID: 33401600)
Annu Rev Pharmacol Toxicol. 1995;35:307-40. (PMID: 7598497)
Dev Cell. 2020 Jun 8;53(5):514-529.e3. (PMID: 32425701)
Sci Rep. 2015 Jun 12;5:11432. (PMID: 26066708)
Immunity. 2014 Jun 19;40(6):989-1001. (PMID: 24909886)
Int J Mol Sci. 2020 Sep 09;21(18):. (PMID: 32916821)
J Virol. 2020 Mar 17;94(7):. (PMID: 31996437)
Nature. 2020 Aug;584(7821):430-436. (PMID: 32640463)
PLoS One. 2019 Apr 15;14(4):e0215072. (PMID: 30986231)
J Exp Med. 2009 Aug 31;206(9):2027-35. (PMID: 19703987)
Front Cell Infect Microbiol. 2018 Feb 06;8:13. (PMID: 29468141)
Int J Mol Sci. 2020 Aug 13;21(16):. (PMID: 32823518)
BMC Bioinformatics. 2018 Dec 19;19(1):534. (PMID: 30567491)
Clin Microbiol Infect. 2021 Aug;27(8):1109-1117. (PMID: 34015535)
Nat Rev Cancer. 2014 Dec;14(12):801-14. (PMID: 25568920)
Nat Methods. 2017 Apr;14(4):417-419. (PMID: 28263959)
Nat Rev Immunol. 2019 Mar;19(3):184-197. (PMID: 30718831)
Front Immunol. 2020 Oct 07;11:576745. (PMID: 33117379)
Immunity. 2018 Jan 16;48(1):19-33. (PMID: 29343438)
Substance Nomenclature:
0 (6-formylindolo(3,2-b)carbazole)
0 (AHR protein, human)
0 (Basic Helix-Loop-Helix Transcription Factors)
0 (Carbazoles)
0 (Receptors, Aryl Hydrocarbon)
EC 1.14.14.1 (CYP1A1 protein, human)
EC 1.14.14.1 (Cytochrome P-450 CYP1A1)
EC 3.4.17.23 (ACE2 protein, human)
EC 3.4.17.23 (Angiotensin-Converting Enzyme 2)
KG60484QX9 (Omeprazole)
Entry Date(s):
Date Created: 20210818 Date Completed: 20210824 Latest Revision: 20231103
Update Code:
20240104
PubMed Central ID:
PMC8371152
DOI:
10.1038/s41598-021-96109-w
PMID:
34404832
Czasopismo naukowe
Since understanding molecular mechanisms of SARS-CoV-2 infection is extremely important for developing effective therapies against COVID-19, we focused on the internalization mechanism of SARS-CoV-2 via ACE2. Although cigarette smoke is generally believed to be harmful to the pathogenesis of COVID-19, cigarette smoke extract (CSE) treatments were surprisingly found to suppress the expression of ACE2 in HepG2 cells. We thus tried to clarify the mechanism of CSE effects on expression of ACE2 in mammalian cells. Because RNA-seq analysis suggested that suppressive effects on ACE2 might be inversely correlated with induction of the genes regulated by aryl hydrocarbon receptor (AHR), the AHR agonists 6-formylindolo(3,2-b)carbazole (FICZ) and omeprazole (OMP) were tested to assess whether those treatments affected ACE2 expression. Both FICZ and OMP clearly suppressed ACE2 expression in a dose-dependent manner along with inducing CYP1A1. Knock-down experiments indicated a reduction of ACE2 by FICZ treatment in an AHR-dependent manner. Finally, treatments of AHR agonists inhibited SARS-CoV-2 infection into Vero E6 cells as determined with immunoblotting analyses detecting SARS-CoV-2 specific nucleocapsid protein. We here demonstrate that treatment with AHR agonists, including FICZ, and OMP, decreases expression of ACE2 via AHR activation, resulting in suppression of SARS-CoV-2 infection in mammalian cells.
(© 2021. The Author(s).)
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies